Vaccine Strategies for HPV-Related Cancers
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 July 2024 | Viewed by 2950
Special Issue Editor
2. Department of Biomedical Engineering, U-M College of Engineering, University of Michigan, Ann Arbor, MI, USA
3. Department of Women's and Gender Studies, U-M College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, USA
Interests: HPV associated diseases; screening and prevention of cervical cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human papillomavirus (HPV) vaccines were purposefully designed to cover HPV 16 and 18, which are associated with about 70% of cervical cancers and about 90% of HPV-associated head & neck and anal cancers. Enough time has elapsed to see early indicators of the reduction in cancers associated with HPV. Other types of HPV will be clinically unmasked as the natural infection types are blocked. Following the change in distribution of HPV types causing the associated cancers will be important to note so that the modeling studies for future prognostic health planning can be modified. HPV vaccine administration appears to be sufficient at one dose for children 9 years of age. Increasing population coverage with a single dose offers more efficiency and equity in vaccine distribution. Understanding person-level and population-level barriers and facilitators to the original vaccine uptake are needed. Separately, the development of pan-HPV vaccines as the next generation vaccine is imperative. Continuing to leave oncogenic HPV types out of the vaccine perpetuates HPV-associated cancer inequities.
Dr. Diane M. Harper
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HPV vaccine uptake
- single dose immunization
- clinical unmasking
- HPV-associated cancers
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: HPV Vaccination in Pediatric and Young Adult Cancer Survivors – Opportunity to Address Gaps in Cancer Prevention and Survivorship
Author: Schlecht
Highlights: • Despite increased risk for HPV-related secondary cancers among pediatric-and-young-adult cancer (PYAC) survivors, HPV vaccination rates remain low in this population.
• Whereas pediatric oncology providers endorse HPV vaccination of PYAC survivors, the responsibility typically remains with primary care providers.
• Cancer transition of care models that integrate evidence-based strategies offer an opportunity for increasing HPV vaccination rates among PYAC survivors.
